

# Gynecology Oncology (GynOnc) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart

## METASTATIC/ UNRESECTABLE

### UCI 22-42

TransCon Toll like receptor (TLR) 7/8  
agonist  
Coord: Jiana Ejbara  
Accrual: 0/5

## MUTATIONS

### UCI 22-78

KSQ-4279 +/- Olaparib or Carboplatin  
Targeting deleterious mutation (germline  
or somatic)  
Coord: Jiana Ejbara  
Accrual: 0/5

### UCI 22-77

AMG794 half-life extended (HLE) BiTE  
molecule targeting CLDN6  
Coord: Jiana Ejbara  
Accrual: 1/8

## PLATINUM-RESISTANT RECURRENCE

<4L

### GOG-3066

Zn-c3

Coord: Jiana Ejbara

Accrual: 0/5

>3L

### GOG-3076

Platinum Doublet + Bevacizumab +/-OlviVec

Coord: Jiana Ejbara

Accrual: 0/5

## PLATINUM-SENSITIVE RECURRENCE

FRa + and >1L

### GOG-3078

Mirvetuximab Soravtansine

Coord: Jiana Ejbara

Accrual: 0/5

SQUAMOUS CELL CARCINOMA

NRG-GY024

Cisplatin + Radiotherapy

Coord: Jiana Ejbara

Accrual: 0/5

## TUMOR MUTATION SPECIFIC

### GOG- 3083

Targeting P53 Wild-type  
SELINEXOR  
Coord: Jiana Ejbara  
Accrual: 0/5

## UTERINE SEROUS

### UCI 20-203

WEE1 inhibition  
Coord: Jiana Ejbara  
Accrual: 0/5

## OVARIAN CANCER

### UCI 21-190

Assessing the Predictive Capability of Circulating Tumor DNA as a Screening Tool for Ovarian Cancer

ctDNA

Coord: Jiana Ejbara

Accrual: 1/36

### UCI 22-40

VIRGO2

Coord: Jiana Ejbara

Accrual:

### UCI 18-120

N-Acetyl-Cysteine (NAC)

Coord: Jiana Ejbara

Accrual:

### UCI 22-62

Tumor Associated Carbohydrate Antigens

Coord: Dr. Liu

Accrual: